Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash & Equivalents (2020 - 2026)

Design Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $298.6 million for Q4 2021.

  • On a quarterly basis, Cash & Equivalents rose 12450.19% to $298.6 million in Q4 2021 year-over-year; TTM through Dec 2021 was $298.6 million, a 12450.19% increase, with the full-year FY2021 number at $298.6 million, up 12450.19% from a year prior.
  • Cash & Equivalents hit $298.6 million in Q4 2021 for Design Therapeutics, down from $357.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for DSGN hit a ceiling of $400.7 million in Q1 2021 and a floor of $2.4 million in Q4 2020.